 |
|
|
| |
Simeprevir (TMC435) with peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a Phase III trial
|
| |
| |
Reported by Jules Levin
48th Annual Meeting of the
European Association for the Study of the Liver
24 April - 28 April 2013 · Amsterdam, The Netherlands
Ira Jacobson,1 Gregory J Dore,2 Graham R Foster,3 Michael W Fried,4 Monica Radu,5 Vladimir V Rafalskiy,6 larysa Moroz,7 antonio Craxì,8 Monika Peeters,9 Oliver lenz,9 sivi Ouwerkerk-Mahadevan,10 Ronald Kalmeijer,11 Maria Beumont-Mauviel9
1Weill Cornell Medical College, New York, NY, USA; 2Kirby Institute, University of New South Wales, Sydney, Australia; 3Queen Mary University of London, Barts Health, London, UK; 4University of North Carolina at Chapel Hill, NC, USA; 5Institutul de Boli infectioase, Bucharest, Romania; 6Smolensk Regional Clinical Hospital, Smolensk Oblast, Russia; 7Vinnytsia National Medical University, Vinnytsia, Ukraine; 8Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy; 9Janssen Infectious Diseases BVBA, Beerse, Belgium; 10Jansssen Research & Development, Beerse, Belgium; 11Janssen Global Services, LLC, Titusville, NJ, USA
|
| |
|
|
|
|
|
